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In this review concerning the state of treatment for
persons with haemophilia A leading up to the develop-
ment and introduction of recombinant factor VIII
products, and beyond, I vividly recall my own feelings
at the time. When I began my fellowship training in
paediatric haematology in the mid-1960s, we almost
always had numerous boys in the hospital, receiving
large volumes of fresh frozen plasma every 6–8 h for
joint or large soft tissue haemorrhages. If they devel-
oped an inhibitor, there was little that we could do.
A short time later, we were able to obtain cryoprecip-
itates, and then, by 1970, intermediate purity, lyophi-
lized FVIII concentrates. These seemed wonderful,
allowing out-patient treatment, and even surgical pro-
cedures! However, it soon became apparent that there
was a price to be paid for the use of these plasma-
derived products as most of our patients developed
hepatitis, and by the early 1980s, AIDS. As a result,
there were attempts to make the lyophilized, plasma-
derived FVIII concentrates safer (improved donor
screening, dry heat treatment, solvent-detergent treat-
ment, pasteurization); however, by 1987, when recom-
binant FVIII concentrates became available for
prelicensure clinical trials, there was genuine excite-
ment! Excitement by me and most of my colleagues
throughout the U.S. and abroad, and also a great deal of
excitement by our patients, many of whom had affected
family members or friends who had developed the
acquired immunodeficiency syndrome (AIDS).
In the 1950s and much of the 1960s, bleeding
episodes in persons with haemophilia were treated with
fresh frozen plasma (FFP), as no one had come up with
a method for separating F VIII or F IX from plasma.
Patients with bleeding episodes were frequently hospi-
talized for infusions of large volumes of FFP given every
6–8 h in an attempt to stop bleeding without pushing
them into congestive heart failure from fluid overload.
A major breakthrough came in 1965, when Dr. Judith
Poole described a simple way of separating FVIII (and
vWF) from plasma which had been frozen and then
thawed in the cold [1]. Almost overnight, cryoprecip-
itates (cold insoluble precipitates) were being produced
by blood collection facilities, for treatment of persons
with haemophilia A. These cryoprecipitates had to be
stored in the frozen state prior to use, and varied in the
amount of FVIII contained. A short time later, two
pharmaceutical companies had developed technologies
to separate FVIII (and FIX) from large pools of donor
plasma, resulting in freeze-dried, lyophilized FVIII
concentrates [2]. These early, intermediate purity FVIII
concentrates were easier to use, as they did not need to
be frozen for storage, and each bottle was labelled with
the amount of FVIII contained. However, neither
cryoprecipitates or these intermediate purity plasma-
derived concentrates were treated for blood-borne
viruses. Once these lyophilized concentrates became
available, treatment for bleeding episodes was much
easier, haemostatic levels of FVIII could easily be
achieved and, in the early 1970s, home treatment
programs sprung up. The latter resulted in earlier
treatment of joint bleeds, and a greater feeling of
independence for those with haemophilia. Many
referred to this period as the ‘golden age’ for haemo-
philia. However, this feeling was short-lived, as in 1981
the Communicable Disease Center (CDC) described the
first three persons with haemophilia A who developed
the acquired immunodeficiency syndrome (AIDS), and
these three were followed by more and more individuals
with haemophilia, many of whom died of its compli-
cations [3–5]. In addition, it had become increasingly
apparent that many persons with haemophilia had been
infected with hepatitis viruses [5] (hepatitis B and so-
called, ‘non-A, non-B’ hepatitis, subsequently called
hepatitis C after the HCV was identified).
These serious complications of treatment resulted in
increased efforts to make treatment safer. Lyophilized,
intermediate purity concentrates were treated with dry
heat [5]. Cryoprecipitates were no longer recommended
for treatment of haemophilia A, being considered less
safe than heat-treated products [6]. In 1981 Haemate P,
a pasteurized FVIII and vWF concentrate became
available in Germany. Predominantly used in Europe,
this product was the first effectively virus-inactivated
FVIII product [7]. Shortly thereafter, other products of
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higher purity were developed, using monoclonal
antibodies to FVIII or von Willebrand Factor (vWF)
[8–11]. The production of these higher purity concen-
trates included multiple purification and virucidal steps
(including heat treatment, solvent detergent treatment)
to reduce the risk of viral transmission. However,
during the relatively short-term hepatitis safety trials
with these high purity FVIII concentrates, inhibitor
assays (which were done at baseline and again at
6 months) demonstrated that some of the previously
untreated subjects (PUPs) developed inhibitors to FVIII
[8,9]. This was alarming at the time, and subsequently
all prospective clinical trials in haemophilia A patients
incorporated more frequent inhibitor assays and a
longer duration of follow-up.
In view of the high rate of transmission of blood-
borne viruses by plasma-derived concentrates in the
1970s and early 1980s, there was a great deal of interest
in the possibility of producing ‘synthetic’ FVIII and FIX.
This possibility became reality for FVIII in 1984 by the
successful determination of structure, and cloning and
expression of the Factor VIII gene by scientists at the
Genetics Institute (in Cambridge, MA) and Genentech
(Berkeley, CA). The prospect of viral safety associated
with FVIII produced from recombinant DNA technol-
ogy was the main advantage, but additionally, rFVIII
could – at least theoretically – become available in
unlimited supply.
These accomplishments, published in a single issue of
‘Nature’ in 1984 [12–15], were remarkable in view of
the size and complexity of the FVIII gene which
encompassed 186,000 base pairs and represented
0.1% of the human X chromosome. In a very short
time thereafter, in collaboration with scientists at
Genentech and the Genetics Institute, two U.S. Phar-
maceutical Companies (Miles, Inc./Cutter Biological,
Berkeley, CA, and Baxter/Hyland Div., Glendale, CA)
accomplished scale-up, purification and standardization
of two rFVIII products for clinical use.
Following preclinical in vitro studies, and studies in
animals, prelicensure clinical trials in patients with
haemophilia A began in 1987 [16]. Safety and efficacy
in treatment of bleeding episodes and in controlling
bleeding in major surgery was documented in adults
[17,18]. Recombinate was licensed for use in the U.S. in
1992 and Kogenate was licensed for use in early 1993.
In January 1989, a study in previously untreated
patients (PUPs) was begun with Kogenate [19], and in
July, 1990, the PUP study with Recombinate began
[20,21]. Clinicians involved in these early trials with
rFVIII products found that it was relatively easy to enrol
subjects, all of whom had heard about AIDS and
hepatitis with plasma-derived products. In both of the
PUP trials, haemostatic responses were excellent and the
products were well tolerated. However, inhibitor anti-
bodies developed early (after a median of 9–11 EDs) in
20–25% of study subjects. Approximately half of the
inhibitors in both PUP studies were ‘high responding’
(>5 BU), whereas the remainder were ‘low responding’
and most of these were transient [22–24]. Nevertheless,
some clinicians became concerned that recombinant
FVIII was causing a higher incidence of inhibitors.
However, earlier studies in infants and children with
severe haemophilia A published in 1992 and 1993 had
documented a higher incidence of inhibitor development
with plasma-derived FVIII (25–50%) [25,26] than pre-
viously thought. It had become increasingly apparent
that, if one looks for inhibitors prospectively, with
laboratory monitoring at frequent intervals, 25–35% (or
even 50%) of PUPs will develop inhibitors after a median
of 9–11 EDs. Roughly one-third of these will disappear
despite continued exposure to FVIII given for episodic
treatment. In addition, it was becoming increasingly
apparent that such findings were not related to a
particular type of product, but were seen with plasma-
derived as well as rFVIII products [27]. Other analyses
were documenting that patient-related factors, such as
the severity of haemophilia, FVIII gene mutation causing
the person’s haemophilia, race, etc., were more impor-
tant determinants of inhibitor development [27].
It had also become apparent that very few persons
with severe haemophilia who had received >50 EDs
with plasma-derived FVIII, developed de novo inhibi-
tors while on rFVIII. These findings led to the 1999
recommendation by the Scientific Subcommittee on
Factor VIII and Factor IX of the ISTH’s Scientific and
Standardization Committee that only previously (and
heavily) treated haemophilia patients would be used for
determining the immunogenicity of any new FVIII
product [28].
Although the benefits of rFVIII products appeared to
be enormous (increased viral safety, greater peace of
mind), there was still some concern over the fact that
the original rFVIII products, Kogenate and Recombin-
ate, contained pasteurized human serum albumin (HSA)
as a stabilizer. Pasteurized HSA had an excellent safety
records, and there was no indication that it caused any
problems in recipients. Nevertheless, HSA was later
replaced with sucrose as a stabilizer (e.g.: Kogenate FS,
which is formulated with sucrose) [29–32].
As newer, so-called ‘second generation’ rFVIII
products were developed, some clinicians worried that
these might be more immunogenic. Pharmacia’s
(Stockholm, Sweden) B-domainless rFVIII (rFVIII SQ)
[33,34] entered prelicensure clinical trials in 1993 in
Europe, and in the U.S. in 1995. No albumin is needed
to stabilize B-domainless rFVIII; however, it was used
in the manufacture of the product. B-domainless
(BDD) rFVIII (ReFacto, now referred to as Xyntha,
Wyeth Pharmaceuticals, Collegeville, PA), has not
been associated with an increased incidence or prev-
alence of FVIII inhibitors as compared with plasma-
derived or full-length rFVIII products in PTPs or PUPs
[35–39].
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From the introduction of the first rFVIII concentrates
in the late 1980s, through each new variation, there
have been carefully designed, long-term, prospective
clinical trials in both PTPs and PUPs to look at safety
and efficacy. These have included frequent inhibitor
assays, as well as other laboratory and clinical obser-
vations. Each of these rFVIII preparations have proven
to be safe and effective. None have resulted in an
increased incidence or prevalence of inhibitors [40]. On
the other hand, a large body of useful information has
been gained from these (and other) studies which have
improved our understanding as to which patients are at
greater risk of developing an inhibitor, what are the
important genetic and environmental risk factors; long-
term viral safety of FVIII products, etc.
So, while there was some concern – particularly about
the possibility of increased immunogenicity – with the
introduction of rFVIII concentrates in 1987, and there
has still been concern with the introduction of each new
rFVIII methodology (now with longer acting rFVIII
preparations), to date, the benefits for patients have far
outweighed any of our worries about risks – especially
in view of the rigours of each prelicensure study designs,
and pharmacovigilance on the part of manufacturers.
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